Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes

Enrico Balleari, Marino Clavio, Eleonora Arboscello, Andrea Bellodi, Andrea Bruzzone, Lisette Del Corso, Maria Vita Lucchetti, Maurizio Miglino, Caterina Passalia, Ivana Pierri, Irene Ponassi, Caterina Oneto, Omar Racchi, Marco Scudeletti, Luana Vignolo, Gabriele Zoppoli, Marco Gobbi, Riccardo Ghio

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in myelodysplastic syndromes (MDS). Early clinical trials showed erythroid responses in no more than 15-25% of patients. In the last decade, a better selection of MDS patients suitable for a therapeutic challenge with rHEPO, alone or in combination with G-CSF, allowed for an increased response-rate, averaging around 40%. More recently, an even higher percentage of responses have been obtained using higher-doses of rHEPO (up to 80,000. IU/weekly) in lower-risk MDS patients. This treatment however, especially at such high doses, is costly and not easily affordable for prolonged periods. The aim of this study was to verify if the use of "standard" doses of rHEPO could induce a satisfying response-rate with a less expensive treatment schedule in IPSS-defined "lower-risk" MDS anemic patients. From January 2005 to December 2009 a total of 55 consecutive anemic (Hb ≤ 10 g/dL) patients (29 males, 26 females, median age 78 years) with low-intermediate-1 risk MDS were treated after informed consent with rHEPO (40,000. IU once a week subcutaneously) for at least 3 months; at the end of this period, erythroid response was assessed, and responders were allowed to continue the treatment indefinitely, whereas non-responders were considered "off study" Both efficacy and safety of the treatment were recorded and evaluated. After 3 months of treatment, 36 out of 55 (65.5%) patients achieved an erythroid response to rHEPO according to IWG 2006 criteria. Higher response-rates to rHEPO were related with both lower IPSS and particularly WPSS scores. Treatment was safe, and only 1 patient had to discontinue the treatment because of unmanageable side-effects. Among the 36 responders, 28 (77%) maintained the response after a median follow-up of 46 months.Our data indicate that standard doses of rHEPO are at least as effective as higher-doses for correcting anemia in lower-risk MDS patients; in this clinical scenario, this schedule allows for a consistent reduction of costs without precluding the achievement of a durable erythroid response.

Original languageEnglish
Pages (from-to)1472-1476
Number of pages5
JournalLeukemia Research
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Myelodysplastic Syndromes
Therapeutics
Anemia
Appointments and Schedules
Granulocyte Colony-Stimulating Factor
Erythropoietin
Informed Consent
Clinical Trials
Safety
Costs and Cost Analysis

Keywords

  • Anemia
  • Erythropoietic stimulating agents
  • Erythropoietin
  • IPSS
  • Low-risk myelodysplastic syndromes
  • WPSS

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. / Balleari, Enrico; Clavio, Marino; Arboscello, Eleonora; Bellodi, Andrea; Bruzzone, Andrea; Del Corso, Lisette; Lucchetti, Maria Vita; Miglino, Maurizio; Passalia, Caterina; Pierri, Ivana; Ponassi, Irene; Oneto, Caterina; Racchi, Omar; Scudeletti, Marco; Vignolo, Luana; Zoppoli, Gabriele; Gobbi, Marco; Ghio, Riccardo.

In: Leukemia Research, Vol. 35, No. 11, 11.2011, p. 1472-1476.

Research output: Contribution to journalArticle

Balleari, E, Clavio, M, Arboscello, E, Bellodi, A, Bruzzone, A, Del Corso, L, Lucchetti, MV, Miglino, M, Passalia, C, Pierri, I, Ponassi, I, Oneto, C, Racchi, O, Scudeletti, M, Vignolo, L, Zoppoli, G, Gobbi, M & Ghio, R 2011, 'Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes', Leukemia Research, vol. 35, no. 11, pp. 1472-1476. https://doi.org/10.1016/j.leukres.2011.05.025
Balleari, Enrico ; Clavio, Marino ; Arboscello, Eleonora ; Bellodi, Andrea ; Bruzzone, Andrea ; Del Corso, Lisette ; Lucchetti, Maria Vita ; Miglino, Maurizio ; Passalia, Caterina ; Pierri, Ivana ; Ponassi, Irene ; Oneto, Caterina ; Racchi, Omar ; Scudeletti, Marco ; Vignolo, Luana ; Zoppoli, Gabriele ; Gobbi, Marco ; Ghio, Riccardo. / Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. In: Leukemia Research. 2011 ; Vol. 35, No. 11. pp. 1472-1476.
@article{041d070cd23d4149ae3adc029479ebdf,
title = "Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes",
abstract = "For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in myelodysplastic syndromes (MDS). Early clinical trials showed erythroid responses in no more than 15-25{\%} of patients. In the last decade, a better selection of MDS patients suitable for a therapeutic challenge with rHEPO, alone or in combination with G-CSF, allowed for an increased response-rate, averaging around 40{\%}. More recently, an even higher percentage of responses have been obtained using higher-doses of rHEPO (up to 80,000. IU/weekly) in lower-risk MDS patients. This treatment however, especially at such high doses, is costly and not easily affordable for prolonged periods. The aim of this study was to verify if the use of {"}standard{"} doses of rHEPO could induce a satisfying response-rate with a less expensive treatment schedule in IPSS-defined {"}lower-risk{"} MDS anemic patients. From January 2005 to December 2009 a total of 55 consecutive anemic (Hb ≤ 10 g/dL) patients (29 males, 26 females, median age 78 years) with low-intermediate-1 risk MDS were treated after informed consent with rHEPO (40,000. IU once a week subcutaneously) for at least 3 months; at the end of this period, erythroid response was assessed, and responders were allowed to continue the treatment indefinitely, whereas non-responders were considered {"}off study{"} Both efficacy and safety of the treatment were recorded and evaluated. After 3 months of treatment, 36 out of 55 (65.5{\%}) patients achieved an erythroid response to rHEPO according to IWG 2006 criteria. Higher response-rates to rHEPO were related with both lower IPSS and particularly WPSS scores. Treatment was safe, and only 1 patient had to discontinue the treatment because of unmanageable side-effects. Among the 36 responders, 28 (77{\%}) maintained the response after a median follow-up of 46 months.Our data indicate that standard doses of rHEPO are at least as effective as higher-doses for correcting anemia in lower-risk MDS patients; in this clinical scenario, this schedule allows for a consistent reduction of costs without precluding the achievement of a durable erythroid response.",
keywords = "Anemia, Erythropoietic stimulating agents, Erythropoietin, IPSS, Low-risk myelodysplastic syndromes, WPSS",
author = "Enrico Balleari and Marino Clavio and Eleonora Arboscello and Andrea Bellodi and Andrea Bruzzone and {Del Corso}, Lisette and Lucchetti, {Maria Vita} and Maurizio Miglino and Caterina Passalia and Ivana Pierri and Irene Ponassi and Caterina Oneto and Omar Racchi and Marco Scudeletti and Luana Vignolo and Gabriele Zoppoli and Marco Gobbi and Riccardo Ghio",
year = "2011",
month = "11",
doi = "10.1016/j.leukres.2011.05.025",
language = "English",
volume = "35",
pages = "1472--1476",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes

AU - Balleari, Enrico

AU - Clavio, Marino

AU - Arboscello, Eleonora

AU - Bellodi, Andrea

AU - Bruzzone, Andrea

AU - Del Corso, Lisette

AU - Lucchetti, Maria Vita

AU - Miglino, Maurizio

AU - Passalia, Caterina

AU - Pierri, Ivana

AU - Ponassi, Irene

AU - Oneto, Caterina

AU - Racchi, Omar

AU - Scudeletti, Marco

AU - Vignolo, Luana

AU - Zoppoli, Gabriele

AU - Gobbi, Marco

AU - Ghio, Riccardo

PY - 2011/11

Y1 - 2011/11

N2 - For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in myelodysplastic syndromes (MDS). Early clinical trials showed erythroid responses in no more than 15-25% of patients. In the last decade, a better selection of MDS patients suitable for a therapeutic challenge with rHEPO, alone or in combination with G-CSF, allowed for an increased response-rate, averaging around 40%. More recently, an even higher percentage of responses have been obtained using higher-doses of rHEPO (up to 80,000. IU/weekly) in lower-risk MDS patients. This treatment however, especially at such high doses, is costly and not easily affordable for prolonged periods. The aim of this study was to verify if the use of "standard" doses of rHEPO could induce a satisfying response-rate with a less expensive treatment schedule in IPSS-defined "lower-risk" MDS anemic patients. From January 2005 to December 2009 a total of 55 consecutive anemic (Hb ≤ 10 g/dL) patients (29 males, 26 females, median age 78 years) with low-intermediate-1 risk MDS were treated after informed consent with rHEPO (40,000. IU once a week subcutaneously) for at least 3 months; at the end of this period, erythroid response was assessed, and responders were allowed to continue the treatment indefinitely, whereas non-responders were considered "off study" Both efficacy and safety of the treatment were recorded and evaluated. After 3 months of treatment, 36 out of 55 (65.5%) patients achieved an erythroid response to rHEPO according to IWG 2006 criteria. Higher response-rates to rHEPO were related with both lower IPSS and particularly WPSS scores. Treatment was safe, and only 1 patient had to discontinue the treatment because of unmanageable side-effects. Among the 36 responders, 28 (77%) maintained the response after a median follow-up of 46 months.Our data indicate that standard doses of rHEPO are at least as effective as higher-doses for correcting anemia in lower-risk MDS patients; in this clinical scenario, this schedule allows for a consistent reduction of costs without precluding the achievement of a durable erythroid response.

AB - For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in myelodysplastic syndromes (MDS). Early clinical trials showed erythroid responses in no more than 15-25% of patients. In the last decade, a better selection of MDS patients suitable for a therapeutic challenge with rHEPO, alone or in combination with G-CSF, allowed for an increased response-rate, averaging around 40%. More recently, an even higher percentage of responses have been obtained using higher-doses of rHEPO (up to 80,000. IU/weekly) in lower-risk MDS patients. This treatment however, especially at such high doses, is costly and not easily affordable for prolonged periods. The aim of this study was to verify if the use of "standard" doses of rHEPO could induce a satisfying response-rate with a less expensive treatment schedule in IPSS-defined "lower-risk" MDS anemic patients. From January 2005 to December 2009 a total of 55 consecutive anemic (Hb ≤ 10 g/dL) patients (29 males, 26 females, median age 78 years) with low-intermediate-1 risk MDS were treated after informed consent with rHEPO (40,000. IU once a week subcutaneously) for at least 3 months; at the end of this period, erythroid response was assessed, and responders were allowed to continue the treatment indefinitely, whereas non-responders were considered "off study" Both efficacy and safety of the treatment were recorded and evaluated. After 3 months of treatment, 36 out of 55 (65.5%) patients achieved an erythroid response to rHEPO according to IWG 2006 criteria. Higher response-rates to rHEPO were related with both lower IPSS and particularly WPSS scores. Treatment was safe, and only 1 patient had to discontinue the treatment because of unmanageable side-effects. Among the 36 responders, 28 (77%) maintained the response after a median follow-up of 46 months.Our data indicate that standard doses of rHEPO are at least as effective as higher-doses for correcting anemia in lower-risk MDS patients; in this clinical scenario, this schedule allows for a consistent reduction of costs without precluding the achievement of a durable erythroid response.

KW - Anemia

KW - Erythropoietic stimulating agents

KW - Erythropoietin

KW - IPSS

KW - Low-risk myelodysplastic syndromes

KW - WPSS

UR - http://www.scopus.com/inward/record.url?scp=80053976546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053976546&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.05.025

DO - 10.1016/j.leukres.2011.05.025

M3 - Article

C2 - 21794914

AN - SCOPUS:80053976546

VL - 35

SP - 1472

EP - 1476

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -